Promising new drug targets rare pain disorder in early trial
NCT ID NCT07262268
First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 16 times
Summary
This study tests a new drug, BHV-7000, to see if it can reduce chronic pain in people with inherited erythromelalgia, a rare genetic condition that causes severe burning pain. Five adults with a specific gene mutation will receive both the drug and a placebo in a crossover design to compare pain levels. The goal is to measure pain intensity and frequency of attacks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL ERYTHROMELALGIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Site-001
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.